Role of KRAS-LCS6 Polymorphism in Advanced NSCLC Patients Treated With Erlotinib or Docetaxel in Second Line Treatment (TAILOR)
Scientific Reports - United Kingdom
doi 10.1038/srep16331
Full Text
Open PDFAbstract
Available in full text
Categories
Date
November 17, 2015
Authors
Publisher
Springer Science and Business Media LLC